ATRX and central nervous system cancer: We subsequently conducted a LASSO analysis (Figure 4A, 4B) and a multivariate Cox analysis (Figure 4C), which identified homeobox A5 (HOXA5), protein tyrosine phosphatase non-receptor type 2 (PTPN2I, WT1 transcription factor (WT1), homeobox D10 (HOXD10), periostin (POSTN), ADAM like decysin 1 (ADAMDEC1) and myosin binding protein H (MYBPH) as independent predictors of survival in ATRX-wt glioma patients.